Interpace Biosciences Balance Sheet Health
Financial Health criteria checks 2/6
Interpace Biosciences has a total shareholder equity of $-11.1M and total debt of $5.7M, which brings its debt-to-equity ratio to -51%. Its total assets and total liabilities are $14.0M and $25.2M respectively. Interpace Biosciences's EBIT is $6.4M making its interest coverage ratio 8.1. It has cash and short-term investments of $2.1M.
Key information
-51.0%
Debt to equity ratio
US$5.69m
Debt
| Interest coverage ratio | 8.1x |
| Cash | US$2.11m |
| Equity | -US$11.15m |
| Total liabilities | US$25.19m |
| Total assets | US$14.04m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IDXG has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IDXG has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IDXG's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: IDXG's debt is well covered by operating cash flow (80.9%).
Interest Coverage: IDXG's interest payments on its debt are well covered by EBIT (8.1x coverage).